Combined Modality Therapy – Page 2

BioNTech Advances PD-L1/VEGF Bispecific Antibody with Encouraging Breast Cancer Trial Results

1 year ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327/PM8002, Clinical Trials, Combined Modality Therapy, Malignant neoplasm of breast, PD-L1/VEGF

BioNTech, PD-L1/VEGF Bispecific Antibody, BNT327/PM8002, Breast Cancer, Oncology Strategy, Clinical Trials, Combination Therapies

Crescent Biopharma’s Public Debut Fueled by PD-1/VEGF Combination Therapy Enthusiasm

1 year ago talkbio0Tagged biopharmaceutical industry, Combined Modality Therapy, inhibitors, Malignant Neoplasms, PD-1/PD-L1, Public Listing, Vascular Endothelial Growth Factor A

PD-1/PD-L1 inhibitors, VEGF inhibitors, Combination therapy, Cancer treatment, Biopharmaceutical industry, Public listing

Sarclisa Gains FDA Approval as First-Line Treatment for Newly Diagnosed Multiple Myeloma

1 year ago talkbio0Tagged Approved, Combined Modality Therapy, first-line, isatuximab, Multiple Myeloma, sanofi, Sarclisa, United States Food and Drug Administration, VRd

Sarclisa, FDA approval, first-line treatment, multiple myeloma, Sanofi, isatuximab, VRd combination therapy.

Bristol Myers Advances Opdualag into Phase 3 Trials for First-Line Lung Cancer

1 year ago talkbio0Tagged Combined Modality Therapy, first-line, LAG-3/PD-1, Malignant neoplasm of lung, Myers, Opdualag, squibb

Opdualag, Bristol Myers Squibb, lung cancer, first-line treatment, phase 3 trials, LAG-3/PD-1 combination therapy

GSK’s Zejula Fails to Meet Overall Survival Goal in First-Line Ovarian Cancer, Combination Therapy Disappoints

1 year ago talkbio0Tagged Combined Modality Therapy, first-line, Maintenance, niraparib, ovarian neoplasm, Overall Survival, Restricted, second-line, SmithKline Beecham, United States Food and Drug Administration, Zejula

Zejula, niraparib, GSK, ovarian cancer, first-line treatment, overall survival, combination therapy, FDA, restriction, second-line maintenance

Merck’s Keytruda-Lenvima Combination Shows Promise in Liver Cancer Treatment

1 year ago talkbio0Tagged Clinical Trials, Combined Modality Therapy, Eisai, Keytruda, Lenvima, Liver and Intrahepatic Biliary Tract Carcinoma, Liver carcinoma

Keytruda, Lenvima, liver cancer, hepatocellular carcinoma, combination therapy, Merck, Eisai, clinical trials.

AstraZeneca Secures Landmark EU Approval for Imfinzi-Lynparza Combo in Endometrial Cancer Treatment

1 year ago talkbio0Tagged Approved, AstraZeneca, Combined Modality Therapy, EU, Imfinzi, Immunotherapy, Inhibitor, Lynparza, Malignant neoplasm of endometrium, Mismatch Repair, Mismatch Repair Deficiency, PARP1 gene, proficient

AstraZeneca, Imfinzi, Lynparza, endometrial cancer, EU approval, combination therapy, immunotherapy, PARP inhibitor, mismatch repair proficient, mismatch repair deficient

Vir Biotechnology Reports Positive Update on Hepatitis Delta Combination and Monotherapy Treatments

2 years ago talkbio0Tagged Clinical Trials, Combined Modality Therapy, Congress (U.S. Legislature), Delta - greek letter, EASL, Hepatitis, Single Agent Therapy, Vir Biotechnology

Vir Biotechnology, Hepatitis Delta, Combination Therapy, Monotherapy, Clinical Trial, EASL Congress

FDA Rejects Elevar and Hengrui Pharma’s Combination Therapy for Liver Cancer

2 years ago talkbio0Tagged Clinical Trials, Combined Modality Therapy, Hengrui Pharmaceuticals, Liver and Intrahepatic Biliary Tract Carcinoma, Rejection (Psychology), United States Food and Drug Administration

FDA, Elevar Therapeutics, Hengrui Pharmaceuticals, liver cancer, combination therapy, rejection, clinical trials.

FDA Grants Approval to ImmunityBio’s Innovative Combination Therapy for Bladder Cancer

2 years ago talkbio0Tagged Approved, Clinical Trials, Combined Modality Therapy, ImmunityBio, Immunotherapy, Malignant neoplasm of urinary bladder, United States Food and Drug Administration

FDA, ImmunityBio, bladder cancer, combination therapy, approval, innovative treatment, immunotherapy, clinical trials